Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Next Previous
Trial Profile

Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Lomustine
  • Indications Glioblastoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Aug 2018.
    • 05 Dec 2017 Results published in a Genentech Media Release.
    • 05 Dec 2017 According to a Genentech media release, company announced that U.S. Food and Drug Administration (FDA) has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy, based on the data from this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top